摘要
目的 探究人血免疫球蛋白在临床上对病毒性脑炎的应用疗效.方法 将我院2013年8月至2014年2月收治的102例病毒性脑炎患者随机分为观察组和对照组,每组各51例,全部患者均符合病毒性脑炎的诊断标准.对照组患者给予阿昔洛韦抗病毒、止惊、降颅内压、冬眠疗法、加压氧和糖皮质激素等常规治疗,观察组患者在对照组的基础上给予人血免疫球蛋白,剂量为500mg/（kg·d）,共3天,比较两组患者的治疗效果.结果 观察组患者各种临床症状的恢复时间明显少于对照组,住院时间也明显少于对照组,差异有统计学意义（P＜0.05）;观察组患者在治疗后并发症的发生率和病死率明显低于对照组,差异有统计学意义（χ^2=18.21,P＜0.05）.结论 阿昔洛韦常规联合人血免疫球蛋白可以更好地协同治疗病毒性脑炎,减少患者临床症状的恢复时间,缩短住院病程,减少并发症的发生,减轻不良反应.
Objective To explore the clinical effect of human serum immunoglobulin in treating viral encephalitis.Methods 102 patients with viral encephalitis in our hospital were randomly divided into the observation group and the control group from August 2013 to February 2014.51 cases in each group and all the patients were consistent with the standard diagnosis of viral encephalitis.The control group of patients were treated with the routine therapy,such as antiviral with acyclovir,convulsions checking,intracranial pressure reducing,hibernation therapy,pressurized oxygen and glucocorticoid.At the same time,the observation group of patients were treated with human serum immunoglobulin [500 mg/（kg d） for 3 days] except for regular treatment as the control group.The therapeutic effect of the two groups patients were compared and analyzed.Results The recovery time of the clinical symptoms such as fever,headache,vomiting,convulsions,consciousness,mental symptom of the observation group patients was much shorter than that of the control group,and the hospitalization days was also less than that of the control group （P 〈 0.05）.The occurrence rate of the complication and death of the observation group were obviously lower than that of the control group （χ^2 =18.21,P 〈0.05）.Conclusions The therapeutic schedule of acyclovir combined with human serum immunoglobulin has obvious effect for treating viral encephalitis in shorting the recovery time and the hospitalization days,reducing the occurrence of complications and the adverse reactions.
出处
《国际病毒学杂志》
2015年第1期36-38,共3页
International Journal of Virology
关键词
人血免疫球蛋白
阿昔洛韦
病毒性脑炎
临床应用
Human serum immunoglobulin
Acyclovir
Viral encephalitis
Clinical application
